0B68 Sato, Takemi - Thomas Jefferson University - Thomas Jefferson University
txs123

Takemi Sato, MD

Contact Dr. Sato

111 South 11th Street
Suite 4240
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization
  2. Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma
  3. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases
  4. Biology of advanced uveal melanoma and next steps for clinical therapeutics
  5. Treatment strategies for clinically detectable metastatic uveal melanoma
  6. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth
  7. Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity
  8. Early arterial stasis during resin-based yttrium-90 radioembolization: Incidence and preliminary outcomes
  9. Tumor necrosis factor-α blockade and development of uveal melanoma: Expected adverse effect or just coincidence?
  10. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: A randomized clinical trial
  11. High-dose vincristine sulfate liposome injection (Marqibo) is not associated with clinically meaningful hematologic toxicity
  12. The potential role of sunitinib targeting melanomas
  13. Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma
  14. A pilot study of sunitinib malate in patients with metastatic uveal melanoma
  15. Uveal melanoma trapped in the temple of doom
  16. Interleukin 6 mediates production of interleukin 10 in metastatic melanoma
  17. Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma
  18. Interleukin 10 in the tumor microenvironment: A target for anticancer immunotherapy
  19. Toxicities after radioembolization with yttrium-90 SIR-spheres: Incidence and contributing risk factors at a single center
  20. Moxifloxacin prophylaxis for chemoembolization or embolization in patients with previous biliary interventions: A pilot study
0